Tags

Type your tag names separated by a space and hit enter

Influence of cannabis use on severity of hepatitis C disease.
Clin Gastroenterol Hepatol 2008; 6(1):69-75CG

Abstract

BACKGROUND & AIMS

Complications of HCV infection are primarily related to the development of advanced fibrosis and whether cannabis use is a risk factor for more severe fibrosis is controversial.

METHODS

Baseline data from a prospective cohort study of 204 persons with chronic HCV infection were used for analysis. The outcome was fibrosis score on biopsy, and the primary predictor evaluated was daily cannabis use.

RESULTS

The median age of the cohort was 46.8 years, 69.1% were male, 49.0% were white, and the presumed route of infection was injection drug use in 70.1%. The median lifetime duration and average daily use of alcohol were 29.1 years and 1.94 drink equivalents per day, respectively. Cannabis use frequency (within prior 12 months) was daily in 13.7%, occasional in 45.1%, and never in 41.2%. Fibrosis stage, assessed by the Ishak method, was F0, F1-2, and F3-6 in 27.5%, 55.4%, and 17.2% of subjects, respectively. Daily compared with non-daily cannabis use was significantly associated with moderate to severe fibrosis (F3-6 vs F1-2) in univariate (odds ratio [OR], 3.21; 95% confidence interval [CI], 1.20-8.56, P = .020) and multivariate analyses (OR, 6.78; 95% CI, 1.89-24.31, P = .003). Other independent predictors of F3-6 were >or=11 portal tracts (compared with <5, OR, 6.92; 95% CI, 1.34-35.7, P = .021) and lifetime duration of moderate to heavy alcohol use (OR per decade, 1.72; 95% CI, 1.02-2.90, P = .044).

CONCLUSIONS

Daily cannabis use is strongly associated with moderate to severe fibrosis, and HCV-infected individuals should be counseled to reduce or abstain from cannabis use.

Authors+Show Affiliations

Department of Medicine, University of California at San Francisco, San Francisco, California, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18166478

Citation

Ishida, Julie H., et al. "Influence of Cannabis Use On Severity of Hepatitis C Disease." Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association, vol. 6, no. 1, 2008, pp. 69-75.
Ishida JH, Peters MG, Jin C, et al. Influence of cannabis use on severity of hepatitis C disease. Clin Gastroenterol Hepatol. 2008;6(1):69-75.
Ishida, J. H., Peters, M. G., Jin, C., Louie, K., Tan, V., Bacchetti, P., & Terrault, N. A. (2008). Influence of cannabis use on severity of hepatitis C disease. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association, 6(1), pp. 69-75. doi:10.1016/j.cgh.2007.10.021.
Ishida JH, et al. Influence of Cannabis Use On Severity of Hepatitis C Disease. Clin Gastroenterol Hepatol. 2008;6(1):69-75. PubMed PMID: 18166478.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Influence of cannabis use on severity of hepatitis C disease. AU - Ishida,Julie H, AU - Peters,Marion G, AU - Jin,Chengshi, AU - Louie,Karly, AU - Tan,Vivian, AU - Bacchetti,Peter, AU - Terrault,Norah A, PY - 2008/1/2/pubmed PY - 2008/2/26/medline PY - 2008/1/2/entrez SP - 69 EP - 75 JF - Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association JO - Clin. Gastroenterol. Hepatol. VL - 6 IS - 1 N2 - BACKGROUND & AIMS: Complications of HCV infection are primarily related to the development of advanced fibrosis and whether cannabis use is a risk factor for more severe fibrosis is controversial. METHODS: Baseline data from a prospective cohort study of 204 persons with chronic HCV infection were used for analysis. The outcome was fibrosis score on biopsy, and the primary predictor evaluated was daily cannabis use. RESULTS: The median age of the cohort was 46.8 years, 69.1% were male, 49.0% were white, and the presumed route of infection was injection drug use in 70.1%. The median lifetime duration and average daily use of alcohol were 29.1 years and 1.94 drink equivalents per day, respectively. Cannabis use frequency (within prior 12 months) was daily in 13.7%, occasional in 45.1%, and never in 41.2%. Fibrosis stage, assessed by the Ishak method, was F0, F1-2, and F3-6 in 27.5%, 55.4%, and 17.2% of subjects, respectively. Daily compared with non-daily cannabis use was significantly associated with moderate to severe fibrosis (F3-6 vs F1-2) in univariate (odds ratio [OR], 3.21; 95% confidence interval [CI], 1.20-8.56, P = .020) and multivariate analyses (OR, 6.78; 95% CI, 1.89-24.31, P = .003). Other independent predictors of F3-6 were >or=11 portal tracts (compared with <5, OR, 6.92; 95% CI, 1.34-35.7, P = .021) and lifetime duration of moderate to heavy alcohol use (OR per decade, 1.72; 95% CI, 1.02-2.90, P = .044). CONCLUSIONS: Daily cannabis use is strongly associated with moderate to severe fibrosis, and HCV-infected individuals should be counseled to reduce or abstain from cannabis use. SN - 1542-7714 UR - https://www.unboundmedicine.com/medline/citation/18166478/full_citation/Influence_of_Cannabis_Use_on_Severity_of_Hepatitis_C_Disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1542-3565(07)01050-6 DB - PRIME DP - Unbound Medicine ER -